Title: Numinus Consolidates Clinics, Study Shows DMT Effective with SSRI, Preprint Questions Psychedelic-induced Neuroplasticity Theory, Potential for a Cole Memo for Psychedelics?
Summary:
– Numinus Wellness, based in Vancouver, is shutting down its Bioscience subsidiary and non-revenue producing research lab as part of efforts to reduce cash expenses and focus on profitability. The company will primarily concentrate on its clinics, training, and clinical research sites. It plans to close its Arizona clinic and consolidate other locations.
– Small Pharma, based in London, released top-line results from a Phase 2a trial that studied the use of DMT in patients with MDD who were also taking SSRI medication. The study found that DMT was safe and effective in both the SSRI cohort and the control group.
– A new preprint challenges the intracellular theory of psychedelic-induced neuroplasticity, suggesting that the drugs’ actions may be mediated by interactions with surface receptors rather than intracellular receptors, as previously thought.
– Legislators have introduced the Validating Independence for State Initiatives on Organic Natural Substances Act of 2023, which seeks to prevent federal intervention in states with psilocybin laws. Although limited to psilocybin, the act could be an important step in ensuring increased access to psychedelic therapies.
